261 related articles for article (PubMed ID: 33740984)
1. "I want to get better, but…": identifying the perceptions and experiences of people who inject drugs with respect to evolving hepatitis C virus treatments.
Goodyear T; Brown H; Browne AJ; Hoong P; Ti L; Knight R
Int J Equity Health; 2021 Mar; 20(1):81. PubMed ID: 33740984
[TBL] [Abstract][Full Text] [Related]
2. "Everybody living with a chronic disease is entitled to be cured": Challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs.
Goodyear T; Ti L; Carrieri P; Small W; Knight R
Int J Drug Policy; 2020 Jul; 81():102766. PubMed ID: 32416525
[TBL] [Abstract][Full Text] [Related]
3. "Stigma is where the harm comes from": Exploring expectations and lived experiences of hepatitis C virus post-treatment trajectories among people who inject drugs.
Goodyear T; Brown H; Browne AJ; Hoong P; Ti L; Knight R
Int J Drug Policy; 2021 Oct; 96():103238. PubMed ID: 33902968
[TBL] [Abstract][Full Text] [Related]
4. "I want to feel young again": experiences and perspectives of young people who inject drugs living with hepatitis C in Vancouver, Canada.
Jacob J; Goodyear T; Coulaud PJ; Hoong P; Ti L; Knight R
Can J Public Health; 2021 Oct; 112(5):947-956. PubMed ID: 34115340
[TBL] [Abstract][Full Text] [Related]
5. 'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs.
Tsui JI; Barry MP; Austin EJ; Sweek EW; Tung E; Hansen RN; Ninburg M; Scott JD; Glick SN; Williams EC
Addict Sci Clin Pract; 2021 Aug; 16(1):52. PubMed ID: 34384494
[TBL] [Abstract][Full Text] [Related]
6. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
[TBL] [Abstract][Full Text] [Related]
7. Life projects: the transformative potential of direct-acting antiviral treatment for hepatitis C among people who inject drugs.
E Williams B; Nelons D; Seaman A; Witkowska M; Ronan W; Wheelock H; Zaman A; Garcia J
Int J Drug Policy; 2019 Oct; 72():138-145. PubMed ID: 30995968
[TBL] [Abstract][Full Text] [Related]
8. Life after hepatitis C cure in HIV-infected people who inject drugs and men who have sex with men treated with direct-acting antivirals in France: Health perceptions and experiences from qualitative and quantitative findings (ANRS CO13 HEPAVIH).
Mora M; Goodyear T; Marcellin F; Shoveller J; Di Beo V; Calzolaio C; Sogni P; Wittkop L; Zucman D; Poizot-Martin I; Lacombe K; Salmon-Céron D; Knight R; Carrieri P
J Viral Hepat; 2020 Dec; 27(12):1462-1472. PubMed ID: 32810905
[TBL] [Abstract][Full Text] [Related]
9. Is hepatitis C virus (HCV) elimination achievable among people who inject drugs in Tijuana, Mexico? A modeling analysis.
Marquez LK; Cepeda JA; Bórquez A; Strathdee SA; Gonzalez-Zúñiga PE; Fleiz C; Rafful C; Garfein RS; Kiene SM; Brodine S; Martin NK
Int J Drug Policy; 2021 Feb; 88():102710. PubMed ID: 32165050
[TBL] [Abstract][Full Text] [Related]
10. Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs.
Yeung A; Palmateer NE; Dillon JF; McDonald SA; Smith S; Barclay S; Hayes PC; Gunson RN; Templeton K; Goldberg DJ; Hickman M; Hutchinson SJ
J Hepatol; 2022 Mar; 76(3):549-557. PubMed ID: 34634387
[TBL] [Abstract][Full Text] [Related]
11. Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada.
Saeed S; Strumpf EC; Moodie EE; Young J; Nitulescu R; Cox J; Wong A; Walmsely S; Cooper C; Vachon ML; Martel-Laferriere V; Hull M; Conway B; Klein MB;
J Int AIDS Soc; 2017 Nov; 20(3):. PubMed ID: 29116684
[TBL] [Abstract][Full Text] [Related]
12. Disparities in uptake of direct-acting antiviral therapy for hepatitis C among people who inject drugs in a Canadian setting.
Socías ME; Ti L; Wood E; Nosova E; Hull M; Hayashi K; Debeck K; Milloy MJ
Liver Int; 2019 Aug; 39(8):1400-1407. PubMed ID: 30653809
[TBL] [Abstract][Full Text] [Related]
13. All-cause mortality before and after DAA availability among people living with HIV and HCV: An international comparison between 2010 and 2019.
Requena MB; Protopopescu C; Stewart AC; van Santen DK; Klein MB; Jarrin I; Berenguer J; Wittkop L; Salmon D; Rauch A; Prins M; van der Valk M; Sacks-Davis R; Hellard ME; Carrieri P; Lacombe K;
Int J Drug Policy; 2024 Feb; 124():104311. PubMed ID: 38184902
[TBL] [Abstract][Full Text] [Related]
14. Patient and provider perceived barriers and facilitators to direct acting antiviral hepatitis C treatment among priority populations in high income countries: A knowledge synthesis.
Amoako A; Ortiz-Paredes D; Engler K; Lebouché B; Klein MB
Int J Drug Policy; 2021 Oct; 96():103247. PubMed ID: 33853727
[TBL] [Abstract][Full Text] [Related]
15. The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries.
Maticic M; Pirnat Z; Leicht A; Zimmermann R; Windelinck T; Jauffret-Roustide M; Duffell E; Tammi T; Schatz E
Harm Reduct J; 2020 Nov; 17(1):89. PubMed ID: 33213481
[TBL] [Abstract][Full Text] [Related]
16. Directly observed hepatitis C treatment with opioid substitution therapy in community pharmacies: A qualitative study.
Gunn J; Higgs P
Res Social Adm Pharm; 2020 Sep; 16(9):1298-1301. PubMed ID: 31003763
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of integrated treatment for hepatitis C virus (HCV) among people who inject drugs in Norway: An economic evaluation of the INTRO-HCV trial.
Lim AG; Aas CF; Çağlar ES; Vold JH; Fadnes LT; Vickerman P; Johansson KA
Addiction; 2023 Dec; 118(12):2424-2439. PubMed ID: 37515462
[TBL] [Abstract][Full Text] [Related]
18. "I'm obviously not dying so it's not something I need to sort out today": Considering hepatitis C treatment in the era of direct acting antivirals.
Wright C; Cogger S; Hsieh K; Goutzamanis S; Hellard M; Higgs P
Infect Dis Health; 2019 May; 24(2):58-66. PubMed ID: 30541692
[TBL] [Abstract][Full Text] [Related]
19. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting.
Read P; Lothian R; Chronister K; Gilliver R; Kearley J; Dore GJ; van Beek I
Int J Drug Policy; 2017 Sep; 47():209-215. PubMed ID: 28587943
[TBL] [Abstract][Full Text] [Related]
20. Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data.
Palmateer NE; McAuley A; Dillon JF; McDonald S; Yeung A; Smith S; Barclay S; Hayes P; Shepherd SJ; Gunson RN; Goldberg DJ; Hickman M; Hutchinson SJ
Addiction; 2021 Oct; 116(10):2893-2907. PubMed ID: 33651446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
